Target Name: PLAA
NCBI ID: G9373
Other Name(s): Phospholipase A-2-activating protein | OTTHUMP00000045176 | PLA2P | phospholipase A2 activating protein | PLAP | PLAP_HUMAN | Phospholipase A2 activating protein, transcript variant 1 | NDMSBA | DOA1 homolog | FLJ12699 | PLAA variant 1 | Phospholipase A-2-activating protein (isoform 1) | FLJ11281 | DOA1 | OTTHUMP00000021164

PLAA: A Protein Involved in Phospholipid Synthesis and Regulation

PLAA (Phospholipase A-2-activating protein) is a protein that is expressed in various cell types, including neurons, endothelial cells, and epithelial cells. It is a 21-kDa protein that is involved in the phosphatidylcholine (phospholipid) synthesis pathway. This pathway is a critical step in the production of phospholipid A2 and phospholipid D2, the main components of cell membranes, which are essential for various cellular processes, including the formation of neural synapses and the regulation of inflammation.

PLAA is a protein that can be activated by various phospholipids, including inositol and choline. When PLAA is activated, it catalyzes the transfer of the phosphate group from the phospholipid to the protein choline. This activation of PLAA is a critical step in the production of phospholipid A2, which is a key component of cell membrane.

PLAA is a protein that can also be regulated by various enzymes, including cyclin D1 (CDK4), which is a transcription factor that regulates cell cycle progression. Cyclin D1 is activated by PLAA, which in turn is regulated by various factors, including Wnt, a developmental signaling molecule.

PLAA is also a protein that can be targeted by small molecules, including inhibitors of PLAA activity. These inhibitors can inhibit the catalytic activity of PLAA, leading to the inhibition of phospholipid A2 synthesis and the downstream regulation of cellular processes.

PLAA is a protein that is being targeted by various drug developers as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. PLAA has been shown to be involved in the regulation of various cellular processes, including cell cycle progression , neurotransmitter synthesis, and inflammation.

PLAA is also a protein that has been shown to play a role in the development and progression of various diseases, including cancer. For example, PLAA has been shown to be involved in the regulation of the growth and survival of cancer cells, and has been shown to be downregulated in various types of cancer.

PLAA is also a protein that has been shown to be involved in the regulation of neurotransmitter synthesis. For example, PLAA has been shown to be involved in the synthesis of the neurotransmitter serotonin, and has been shown to play a role in the regulation of its levels in the brain.

PLAA is also a protein that has been shown to be involved in the regulation of inflammation. For example, PLAA has been shown to be involved in the production of pro-inflammatory cytokines, and has been shown to play a role in the regulation of their levels in various types of inflammation.

In conclusion, PLAA is a protein that is involved in various cellular processes, including phosphatidyl choline synthesis, cell cycle progression, neurotransmitter synthesis, and inflammation. It is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases . Further research is needed to fully understand the role of PLAA in these processes and to develop effective inhibitors of PLAA activity.

Protein Name: Phospholipase A2 Activating Protein

Functions: Plays a role in protein ubiquitination, sorting and degradation through its association with VCP (PubMed:27753622). Involved in ubiquitin-mediated membrane proteins trafficking to late endosomes in an ESCRT-dependent manner, and hence plays a role in synaptic vesicle recycling (By similarity). May play a role in macroautophagy, regulating for instance the clearance of damaged lysosomes (PubMed:27753622). Plays a role in cerebellar Purkinje cell development (By similarity). Positively regulates cytosolic and calcium-independent phospholipase A2 activities in a tumor necrosis factor alpha (TNF-alpha)- or lipopolysaccharide (LPS)-dependent manner, and hence prostaglandin E2 biosynthesis (PubMed:18291623, PubMed:28007986)

More Common Targets

PLAAT1 | PLAAT2 | PLAAT3 | PLAAT4 | PLAAT5 | PLAC1 | PLAC4 | PLAC8 | PLAC8L1 | PLAC9 | PLAC9P1 | PLAG1 | PLAGL1 | PLAGL2 | Plasma Membrane Calcium ATPase | PLAT | Platelet Glycoprotein Ib Complex | Platelet-activating factor acetylhydrolase isoform 1B complex | Platelet-Derived Growth Factor (PDGF) | Platelet-Derived Growth Factor Receptor | PLAU | PLAUR | PLB1 | PLBD1 | PLBD1-AS1 | PLBD2 | PLCB1 | PLCB2 | PLCB3 | PLCB4 | PLCD1 | PLCD3 | PLCD4 | PLCE1 | PLCE1-AS2 | PLCG1 | PLCG1-AS1 | PLCG2 | PLCH1 | PLCH2 | PLCL1 | PLCL2 | PLCXD1 | PLCXD2 | PLCXD3 | PLCZ1 | PLD1 | PLD2 | PLD3 | PLD4 | PLD5 | PLD6 | PLEC | PLEK | PLEK2 | PLEKHA1 | PLEKHA2 | PLEKHA3 | PLEKHA4 | PLEKHA5 | PLEKHA6 | PLEKHA7 | PLEKHA8 | PLEKHA8P1 | PLEKHB1 | PLEKHB2 | PLEKHD1 | PLEKHF1 | PLEKHF2 | PLEKHG1 | PLEKHG2 | PLEKHG3 | PLEKHG4 | PLEKHG4B | PLEKHG5 | PLEKHG6 | PLEKHG7 | PLEKHH1 | PLEKHH2 | PLEKHH3 | PLEKHJ1 | PLEKHM1 | PLEKHM1P1 | PLEKHM2 | PLEKHM3 | PLEKHN1 | PLEKHO1 | PLEKHO2 | PLEKHS1 | PLET1 | Plexin | PLG | PLGLA | PLGLB1 | PLGLB2 | PLGRKT | PLIN1 | PLIN2 | PLIN3 | PLIN4